Mhínigh athbhreithniú a scríobh Young, MD, Ionad Ailse Anderson, SAM cur i bhfeidhm imdhíteiripe inhibitor PD-1 i linfóma B-chill. (Fuil. Leagan ar líne an 8 Samhain, 2017. doi: 10.1182 / blood-2017-07-740993.) PD-1 imdhíonachta ..
Clinic Cleveland na Stát Aontaithe Eric D. His et al. Tuairiscíodh go n-athraíonn an diagnóis ar linfóma cille T forimeallach (PTCL) sna Stáit Aontaithe go mór, agus go minic bíonn faisnéis thábhachtach feinitíopach ann chun idirdhealú iomlán a dhéanamh.
Tá siadaí aibí T-chill, mar shampla linfóma T-chill neamh-Hodgkin, an-ionrach agus frithsheasmhach ó dhrugaí, agus is minic a bhíonn prognóis lag ag othair. Le déanaí, d’fhoilsigh sraith dhá alt “Nature” léirmhíniú nua ar an bpataigin.
Obesity not only runs counter to the aesthetics of people, but also causes many chronic diseases. Some studies have shown that body mass index (BMI) is related to the risk of cancer in certain parts (such as the digestive system),..
Yesterday, the US FDA announced the approval of Seattle Genetics' antibody-drug conjugate Adcetris (brentuximab vedotin) in combination with chemotherapy for patients with previously treated stage III or IV classic Hodgkin's lymph..
Léiríonn taighde New Clinic Cleveland don chéad uair go bhféadfadh ibrutinib (ibrutinib) atá ceadaithe ag FDA le haghaidh liomfóma agus leoicéime cabhrú freisin le cóireáil a dhéanamh ar na siadaí inchinn is coitianta agus is marfach, agus féadfar é a úsáid lá amháin in othair le gliobla.
Bone marrow fibrosis is a rare chronic disease of bone marrow hematopoietic cells. They benefit from JAK2 inhibitor drugs: symptom relief, prolonged survival, and improved quality of life. However, two or three years after starti..
On June 12-13, FDA approved two new indications for K drug, just the day before the K drug was approved for the treatment of cervical cancer. One day later, the US FDA approved pembrolizumab (Keytruda, pembrolizumab) for the trea..
In the United States, more than 70,000 people are diagnosed with non-Hodgkin's lymphoma each year, which is caused by excessive proliferation of immune cells in the body's lymph nodes. The most common is diffuse large B-cell lymp..
Le blianta beaga anuas, tá an éifeacht atá ag coscairí seicphointe imdhíonachta ar chóireáil liomfóma Hodgkin (HL) go hiontach, ach ní mór an galar a shárú níos críochnúla fós. Dúirt Cathaoirleach Ghrúpa Lymphoma Chlinic Mhaigh Eo Ansell..